Aurinia Pharmaceuticals 株価情報 (NASDAQ: AUPH)

最新ニュース Aurinia Pharmaceuticals (NASDAQ:AUPH) 株価情報

Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Aurinia Pharmaceuticals Inc - Common Shares

Aurinia Pharmaceuticals Inc

<a href="https://www.bloomberg.com/news/articles/2025-05-13/united-air-warns-flyers-of-reduced-newark-service-through-summer?embedded-checkout=true">https://www.bloomberg.com/news/articles/2025-05-13/united-air-warns-flyers-of-reduced-newark-service-through-summer?embedded-checkout=true</a>

News

General

'United Air Warns Flyers of Reduced Newark Service Through Summer'- Bloomberg

B of A Securities analyst Jeffrey Spector maintains Extra Space Storage (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EXR#NYSE">EXR</a>) with a Neutral and raises the price target from $155 to $161.

Price Target

Analyst Ratings

B of A Securities Maintains Neutral on Extra Space Storage, Raises Price Target to $161

Murphy USA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MUSA#NYSE">MUSA</a>) has outperformed the market over the past 10 years by 11.23% on an annualized basis producing an average annual return of 21.91%. Currently, Murphy USA has a market capitalization of $8.70 billion. 
Buying $1000 In MUSA: If an investor had bought $1000 of MUSA stock 10 years ago, it would be worth $7,305.16 today based on a price of $439.48 for MUSA at the time of writing.
<h3>Murphy USA's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747155115_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

MUSA

Here's How Much You Would Have Made Owning Murphy USA Stock In The Last 10 Years

JPMorgan analyst Doug Anmuth <a href="https://www.benzinga.com/quote/NFLX/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained an Overweight</a> rating on Netflix Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NFLX#NASDAQ">NFLX</a>) with a price target of $1,150 on Monday.
Netflix shares are +30% above post-tariff lows, significantly outperforming the SPX +15%, driven by the streaming giant&#8217;s defensive subscription nature &amp; streaming leadership against macro and tariff uncertainty, Anmuth noted.
The analyst said some of that may reverse shortly as trade relief shifts investors more to tariff-impacted names that have lagged in recent weeks.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/05/45192411/netflix-stock-drops-as-trumps-proposed-tariffs-on-foreign-films-spark-concerns" rel="noreferrer noopener">Netflix And Other Streaming Stocks Slide As Trump&#8217;s Proposed Tariffs On Foreign Films Sparks Concern</a>
More fundamentally, heading into Netflix&#8217;s Upfronts this week, he expects the company to provide updated Ad Tier MAUs, announce further expansion of the Netflix Ads Suite across international markets, and highlight key Live/Sports content.
Anmuth remains bullish on Netflix&#8217;s growing Ad Tier scale and projected Ad Tier subscribers of 60 million+ by the end of 2025, which ties to 140 million+ MAUs, assuming ~2.3 times MAUs or subscribers.
Now that Netflix has reached sufficient scale, the company is shifting its focus more to monetization. The analyst projected advertising revenue (ex-subscription) of $3.0 billion in 2025, more than doubling from $1.4 billion in 2024. Beyond advertising, the 2025 content slate remains strong, with key second-quarter releases including &#8220;Nonnas,&#8221; &#8220;Sirens,&#8221; &#8220;Big Mouth&#8221; Season 8, &#8220;Fear Street: Prom Queen,&#8221; &#8220;Ginny &amp; Georgia&#8221; Season 3, &#8220;Tires&#8221; Season 2, &#8220;FUBAR&#8221; Season 2, and &#8220;Squid Game&#8221; Season 3.
Potential tariff implementation on films produced outside the U.S. has been a growing topic, but the implementation remains unclear, and it is difficult to size the potential financial impact.
Anmuth noted that Netflix produces original content across 50+ countries globally, and 3P articles suggest that 50%+ of content is produced internationally. However, Netflix&#8217;s contributions to the U.S. are significant, with 9k+ full-time U.S. employees, 2.2 million square feet of corporate office space in the U.S., and 3.1 million square feet of studio space across 60 U.S. soundstages.
Anmuth remained positive on Netflix, and his bull thesis reflects healthy double-digit revenue growth in both fiscal 2025 and 2026, continued operating margin expansion while increasing investments in content, ads, and gaming, multi-year free cash flow ramp on improving profit and cash content discipline, with growing buybacks, the company&#8217;s strong streaming leadership position, the potential to become global TV as Netflix expands its ~308 million member base (700 million+ global audience) across the 750 million+ broadband HHs ex-Russia &amp; China.
Anmuth projected average 2025 and 2026 growth of +13% for foreign-exchange-neutral revenue, +22% for operating income, +24% for GAAP EPS, and +30% for free cash flow, which the analyst noted supports Netflix&#8217;s premium valuation.
Price Action: NFLX stock is up 3.1% to $1,144.61 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/04/44826592/netflix-wants-to-be-the-next-1-trillion-company-analyst-highlights-growth-path" target="_blank" rel="noreferrer noopener">Netflix Wants To Be The Next $1 Trillion Company, Analyst Highlights Growth Path</a></li>
</ul>
Photo: Shutterstock

Entertainment

Reiteration

NFLX

Netflix Rally Could Cool As Trade Relief Shifts Focus, JPMorgan Still Bullish

China-based&nbsp;JD.com,&nbsp;Inc.&nbsp;(NASDAQ:&nbsp;JD) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45369198/jd-com-announces-first-quarter-2025-results" rel="noreferrer noopener">fiscal first-quarter</a> results on Tuesday. The company reported a quarterly revenue growth of 15.8%&nbsp;year-over-year&nbsp;to $41.5 billion, beating the&nbsp;analyst consensus estimate of $40.2 billion.
JD posted&nbsp;an adjusted net income per ADS of $1.16, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate</a> of $1.05.
Also Read: <a target="_blank" href="https://www.benzinga.com/government/regulations/25/05/45348699/us-listed-chinese-stocks-rally-as-countries-agree-to-ease-import-tariffs" rel="noreferrer noopener">US Listed Chinese Stocks Rally As Countries Agree To Ease Import Tariffs</a>
<h1 class="wp-block-heading">JD Segment Performance</h1>
JD.com&#8217;s&nbsp;net product revenue increased by 16.2%&nbsp;Y/Y&nbsp;at $33.39 billion. Net service revenues rose 14.0%&nbsp;Y/Y&nbsp;to $8.1 billion.&nbsp;
JD Retail revenue climbed 16.3%&nbsp;Y/Y&nbsp;to $36.36 billion, Logistics revenue gained 11.5% Y/Y to $6.47 billion, and the new business revenues grew 18.1% Y/Y to $793 million.
JD.com&#8217;s marketing expenses rose 13.9% to $1.5 billion in the quarter, forming 3.5% of revenues, down by 10 bps.
<h1 class="wp-block-heading">Margins</h1>
Operating margin was 3.5% for the quarter, compared to 3.0% Y/Y. Adjusted operating margin improved by 50 bps Y/Y to 3.9%. JD Retail&#8217;s operating margin rose 80 bps to 4.9%.&nbsp;
Adjusted EBITDA increased 27.0% Y/Y to $1.9 billion, with a 4.6% margin, up by 50 bps.
JD.com used $2.98 billion in free cash flow for the quarter and $2.52 billion in operating cash flow. The company held $28.0 billion in cash and equivalents as of March 31, 2025.
CEO Sandy Xu attributed the quarterly results to improving consumer sentiment and continued enhancements to JD&#8217;s supply chain capabilities and user experience.
Price Action: JD stock is up 5.31% at $37.97 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45365162/cathie-wood-makes-bullish-move-on-baidu-ark-adds-30k-shares-amid-china-us-trade-thaw" target="_blank" rel="noreferrer noopener">Cathie Wood Makes Bullish Move On Baidu: Ark Adds 30K+ Shares Amid China-US Trade Thaw</a></li>
</ul>
Photo by Freer via Shutterstock

Asia

Earnings

Movers

Tech

JD.com Clocks Strong Q1 Retail And Logistics Growth Fueled By Cash Burn

BMO Capital analyst Rufus Hone maintains Repay Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPAY#NASDAQ">RPAY</a>) with a Market Perform and lowers the price target from $7 to $5.

RPAY

BMO Capital Maintains Market Perform on Repay Holdings, Lowers Price Target to $5

UBS analyst Joshua Spector maintains Orion (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OEC#NYSE">OEC</a>) with a Buy and lowers the price target from $17 to $15.

UBS Maintains Buy on Orion, Lowers Price Target to $15

BMO Capital analyst Etzer Darout maintains Terns Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TERN#NASDAQ">TERN</a>) with a Outperform and lowers the price target from $26 to $15.

TERN

BMO Capital Maintains Outperform on Terns Pharma, Lowers Price Target to $15

WIIM

Johnson & Johnson shares are trading lower after Leerink Partners downgraded the stock from Outperform to Market Perform and lowered its price target from $169 to $153.

UBS analyst Michael Goldsmith maintains Alpine Income Property Tr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PINE#NYSE">PINE</a>) with a Neutral and lowers the price target from $17 to $16.

PINE

UBS Maintains Neutral on Alpine Income Property Tr, Lowers Price Target to $16

AMAT

ASML

AVGO

INTC

KLAC

LEDS

LRCX

LSCC

MCHP

MRVL

NVDA

NXPI

QCOM

RMBS

SIMO

iShares PHLX SOX Semiconductor Sector Index Fund

SOXX

TSEM

Shares of semiconductor and chip stocks are trading higher as investors assess US-China trade progress and Saudi Arabia deals.

President Donald Trump on Monday signed a sweeping executive order aimed at drastically reducing prescription <a href="https://www.benzinga.com/topic/drug-prices">drug prices in the U.S. </a>
What Happened: y tying them to the lowest prices paid in comparable foreign countries — a policy known as <a href="https://www.benzinga.com/trading-ideas/movers/25/05/45381118/cvs-health-cigna-stocks-dip-tuesday-whats-going-on">&#8220;most-favored-nation&#8221; pricing.</a>
The executive order is <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">a response</a> to what Trump described as &#8220;unreasonable or discriminatory&#8221; practices abroad. 
"In case after case, our citizens pay massively higher prices than other nations pay for the same exact pill, from the same factory, effectively subsidizing socialism aboard [abroad] with skyrocketing prices at home," Trump said in <a href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-put-american-patients-first-by-lowering-drug-prices-and-stopping-foreign-free-riding-on-american-pharmaceutical-innovation/">a statement</a>. 
Drug manufacturers have 30 days to voluntarily lower prices for prescription drugs in the U.S. to match those paid in other advanced nations.&nbsp;
If companies do not comply, the Department of Health and Human Services, led by Robert F. Kennedy Jr., is tasked with developing rules to enforce most-favored nation (MFN) pricing or other regulatory measures.&nbsp;
The HHS is also instructed to establish mechanisms for Americans to purchase drugs directly from manufacturers at the MFN price, bypassing pharmacy benefit managers (PBMs) and other intermediaries.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/05/45378427/trump-wants-to-kickstart-nuclear-development-these-5-stocks-could-boom?utm_source=articleShare">Trump Wants To Kickstart Nuclear Development: These 5 Stocks Could Boom</a>&nbsp;
Why It Matters: The executive order is a rare show of common ground between the Trump administration and Democratic leaders like Senator Bernie Sanders, who has long fought for laws aimed at making medicine more affordable.
And Trump has tried this before. During his first term, he signed a similar <a href="https://trumpwhitehouse.archives.gov/presidential-actions/executive-order-lowering-drug-prices-putting-america-first-2/">order</a> that the courts ultimately blocked after the pharmaceutical industry lobbied against it.
Sanders fears the same thing might happen again. In a <a href="https://bsky.app/profile/did:plc:upw5n2uwhzubjajdtqaufsek/post/3loyh44tra225?ref_src=embed&amp;ref_url=https%253A%252F%252Fwww.commondreams.org%252Fnews%252Ftrump-executive-order-drug-prices">post</a> on the Bluesky social network, he agreed that it is &#8220;an outrage that the American people pay, by far, the highest prices in the world for prescription drugs.&#8221;
&#8220;As Trump well knows, his executive order will be thrown out by the courts,&#8221; said Sanders. &#8220;If Trump is serious about making real change rather than just issuing a press release, he will support legislation I will soon be introducing to make sure we pay no more for prescription drugs than people in other major countries. If Republicans and Democrats come together on this legislation, we can get it passed in a few weeks.&#8221;
Pharmaceutical stocks dropped in Monday's premarket trading, but recovered into positive territory by the market close.
Analysts and investors decided the order was less-specific than feared and likely to be challenged in court. 
"A drug pricing announcement had been expected for a while now and had weighed on stocks in this sector, so the official executive order doesn&#8217;t seem to be impacting sentiment too much,&#8221; said James Harlow, senior vice president at Novare Capital Management, per Reuters.&nbsp;
In contrast, Trump&#8217;s comments of &#8220;cutting out the middlemen&#8221; weighed on shares of companies that own pharmacy benefit managers like The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), CVS Health Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) and UnitedHeath Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>).&nbsp;
"I would cut out the middlemen," Trump said. "Everybody should equalize. Everybody should pay the same price."
Shares of UnitedHealth plunged Tuesday after<a href="https://www.benzinga.com/25/05/45373368/unitedhealth-stock-plunges-names-new-ceo-suspends-2025-guidance"> the company</a> pulled its 2025 outlook, citing that care activity continued to accelerate and CEO Andrew Witty unexpectedly resigned.&nbsp;
Read Next: <a href="https://www.benzinga.com/25/05/45354683/tesla-probably-wont-make-money-on-ride-hailing-for-years-gary-black-says?utm_source=articleShare">Tesla Robotaxi Hopes Dashed By Uber, Lyft: No Fast Lane To Profits, Warns Investor Gary Black&nbsp;</a>
What To Watch: The executive order threatens the PBM business model by enabling direct-to-consumer drug purchases, which could significantly reduce the need for PBMs&#8217; negotiating and administrative services. However, legal experts have raised concerns about the legality of direct-to-consumer sales.&nbsp;
"This order's suggestion of broader or direct-to-consumer importation stretches well beyond what the statute allows," warned health policy lawyer, Paul Kim, per the New York Post.&nbsp;
Investors in the healthcare sector may choose to mitigate risk and exposure to PBMs through a diversified healthcare ETF like the SPDR Select Health Care Sector Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) which holds shares of pharmaceuticals, health care equipment and supplies and health care providers.&nbsp;
An ETF like the iShares U.S. Medical Devices ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ITI#NYSE">ITI</a>) which tracks the Dow Jones U.S. Select Medical Equipment Index and invests in leading U.S. medical device companies also offers exposure to the healthcare industry while reducing exposure to pharmaceutical benefit managers.&nbsp;
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45319531/cathie-wood?utm_source=articleShare">Cathie Wood Says AI Will &#8216;Disrupt The Traditional World Order&#8217; And Replace Search Engines Like Google</a>&nbsp;</li>
</ul>
Image: Shutterstock

Large Cap

Sector ETFs

Specialty ETFs

Health Care

Politics

ETFs

Trump Again Promises Lower Drug Prices By 'Cutting Out Middlemen' Like UnitedHealth, CVS: Will It Work This Time?

Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) and Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>) have posted strong gains over the past week, rallying more than 25% as Bitcoin hovers near all-time highs, fueling momentum across the meme coin sector.
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>$0.2387</td>
<td>+2%</td>
<td>+43%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>$0.00001603</td>
<td>+0% </td>
<td>+28% </td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td> $0.00001438</td>
<td>+4% </td>
<td>+84% </td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Trader Tardigrade pointed out that Dogecoin is entering the final stage of its Cycle 3, typically the most explosive phase, and says momentum is building fast.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> is finalizing Cycle 3 &#x1f525; This is the most powerful move in the cycle. Let&#39;s see how it goes &#x1f680;<a href="https://twitter.com/search?q=%24Doge&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$Doge</a> <a href="https://t.co/ut8s0LiMPp">pic.twitter.com/ut8s0LiMPp</a>
&mdash; Trader Tardigrade (@TATrader_Alan) <a href="https://twitter.com/TATrader_Alan/status/1922216007000813797?ref_src=twsrc%5Etfw">May 13, 2025</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Rekt Capital <a href="https://x.com/rektcapital/status/1922009907198328913">highlighted</a> DOGE currently retesting a key pre-halving resistance zone as new support. If this level holds, the next upside target is $0.27.
Meanwhile, CryptoGuru <a href="https://x.com/BDCryptoGuru/status/1922242833328570681">noted</a> Shiba Inu has broken out cleanly from a descending channel with a 68% move. 
As long as the current pullback holds above this level, the bullish setup remains intact. 
He advises watching for volume and support confirmation for potential continuation.
Statistics: Glassnode data shows DOGE futures open interest up 63.9% over the past week, from $989 million to $1.62 billion, even as price momentum cools. This signals heightened speculative interest
Shibburn data shows that 14.6 million SHIB tokens were burned in the past 24 hours, continuing the trend of reducing supply, a key factor that can contribute to upward price pressure.
Shibariumscan reports daily transactions rose from 4.16 million to 4.21 million within a single day, signaling growing on-chain activity.
According to IntoTheBlock, Shiba Inu also saw a massive 214.3% spike in large transaction volume over the same period. 
Daily active addresses climbed 13.8%, while high-value transactions (over $100,000) jumped from 115 to 195 — underscoring rising interest from larger players and increasing network engagement.
Read Next:&nbsp;
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45314812/mark-cuban-slams-memecoins-says-they-set-a-bad-example-for-new-crypto-investors">Mark Cuban Slams Memecoins, Says They Set A &#8216;Bad Example&#8217; For New Crypto Investors</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin, Shiba Inu Surge Over 25% In 7 Days: What Is Going On?

UBS analyst Dan Leonard maintains 10x Genomics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) with a Neutral and lowers the price target from $14 to $12.

UBS Maintains Neutral on 10x Genomics, Lowers Price Target to $12

UBS analyst Michael Goldsmith maintains W.P. Carey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WPC#NYSE">WPC</a>) with a Neutral and lowers the price target from $66 to $63.

UBS Maintains Neutral on W.P. Carey, Lowers Price Target to $63

International Game Technology (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) shares are trading lower on Tuesday, after the <a href="https://www.benzinga.com/movers" target="_blank" rel="noreferrer noopener">company reported first-quarter results.</a>
The company reported quarterly adjusted earnings per share of nine cents, missing the<a href="https://www.benzinga.com/pressreleases/25/05/n45370958/international-game-technology-plc-reports-first-quarter-2025-results" target="_blank" rel="noreferrer noopener"> analyst consensus estimate of 11 cents</a>. Quarterly sales of $583 million (down 12% year over year) missed the street view of $627.84 million.
Instant ticket and draw-based revenue was affected by calendar shifts. Normalized global same-store sales rose 1.4%, adjusting for leap year and scheduling differences across key regions.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/05/45382639/bank-of-america-bets-on-brick-and-mortar-expansion-plans-include-60-markets-worldwide" rel="noreferrer noopener">Bank Of America Bets On Brick-And-Mortar, Expansion Plans Include 60 Markets Worldwide</a>
Adjusted EBITDA fell 24% on a year-over-year basis to $250 million, while adjusted EBITDA margin contracted to 42.8% from 49.5% a year ago.
Adjusted EBITDA declined due to the absence of strong profit flow-through from elevated U.S. multi-state jackpot sales and related incentives seen last year.
Additional pressure came from new growth investments, rebranding costs tied to separating Lottery from Gaming &amp; Digital, and adverse foreign currency translation.
Operating income slumped 37% year-over-year to $138 million, while operating margin contracted to 23.7% from 33.1% in the year-ago period.
Operating income declined, mainly due to factors impacting adjusted EBITDA. A foreign exchange loss replaced last year's gain, driven by EUR/USD debt fluctuations.
As of March 31, 2025, total liquidity stood at $2.2 billion. This included $600 million in unrestricted cash and $1.5 billion in available credit capacity.
Dividend: The company declared a quarterly cash dividend of 20 cents per common share. The dividend will be paid on June 12 to shareholders of record as of May 29.
Outlook: International Game Technology narrowed its FY2025 sales guidance to $2.55 billion, down from the previous range of $2.55 billion to $2.65 billion, and compared with the $2.57 billion estimate.
&#8220;Given lower U.S. multi-state jackpot activity and the current worsening macroeconomic environment, we believe it is likely we will be at the low end of the full-year revenue and Adjusted EBITDA guidance provided in February,&#8221; said Max Chiara, CFO of IGT.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45369770/whos-going-to-buy-2-trillion-worth-of-paper-macro-expert-calls-wall-street-rally-a-headline-sugar-rush-as-treasury-yield-spike-signals-bigger-trouble" target="_blank" rel="noreferrer noopener">‘Who's Going To Buy $2 Trillion Worth Of Paper?' Macro Expert Calls Wall Street Rally A ‘Headline Sugar Rush' As Treasury Yield Spike Signals Bigger Trouble</a></li>
</ul>
Photo: IGT Wheel of Fortune DiamondRS Premium Wheel Cabinet Makes US Casino Debut, Courtesy IGT

Equities

Gaming

Guidance

Global

Markets

International Game Technology Misses Q1 Earnings During Margin Pressure; Trims Outlook On Weaker Jackpot Sales, Macroeconomic Headwinds

JPMorgan analyst Samik Chatterjee <a href="https://www.benzinga.com/quote/AAPL/analyst-ratings" target="_blank" rel="noreferrer noopener">maintained an Overweight</a> rating on Apple Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) on Monday.
The latest ruling from Judge Yvonne Gonzalez Rogers has led to a lot of investor questions around the impact on App Store revenues from the use of alternative payments with no obligation to pay Apple a fee relative to the most recent setup of leveraging alternative payments, but with a 27% fee to Apple, after the initial ruling from the same judge enabled Steering.
Chatterjee needed to reiterate some key aspects before getting into scenario analysis to address investor questions.
Also Read: <a href="https://www.benzinga.com/tech/25/05/45320459/nvidia-apple-face-bigger-risks-from-china-trade-talks-than-any-boost-from-uk-deal-analyst-says" target="_blank" rel="noreferrer noopener">Nvidia, Apple Face Bigger Risks From China Trade Talks Than Any Boost From UK Deal, Analyst Says</a>
The ruling only relates to the steering rules that required Apple to enable steering or link-outs for applications, and there are no implications for In-App Purchase (IAP), as per the analyst. Apple has already appealed the ruling, and the analyst expects a long, drawn-out process. The key watchpoint is how quickly Apple can get a stay on the changes required by the latest ruling while pursuing the appeal process, the analyst said.
He noted the outcome during a long-drawn process could eventually see a fee lower than 27% to enable competition but materially higher than 0%, implying that Apple&#8217;s IP in its App Store is limited.
Chatterjee noted that the IP behind the App Store will have to be compensated; the latest court ruling effectively voids the value of the IP.
Publishers or Applications, like Match, have said they saw a 1/3rd take rate on alternative payments offered on Google app stores, but those scenarios included payments within the App.
According to the analyst, the cost of supporting transactions and discounts to promote link-out adoption will limit the economics for the vast majority of publishers.
Chatterjee&#8217;s scenario analysis implies modest EPS headwinds at most for Apple (2%-3%) if the company is unable to get a stay in the appeals process and an impact of ~80 to ~200 bps on the growth of Services revenue.
Price Action: AAPL stock is up 0.25% at $211.37 at last check Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45324239/apples-upcoming-chips-aim-to-challenge-meta-in-the-smart-glasses-battle-report" target="_blank" rel="noreferrer noopener">Apple&#8217;s Upcoming Chip Aims To Challenge Meta In Smart Glasses Battle: Report</a></li>
</ul>
Photo: Akhenaton Images/Shutterstock

AAPL

JPMorgan Sees Manageable Impact For Apple If App Store Appeal Fails

UBS analyst Mark Carden maintains Warby Parker (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WRBY#NYSE">WRBY</a>) with a Neutral and lowers the price target from $23 to $20.

WRBY

UBS Maintains Neutral on Warby Parker, Lowers Price Target to $20

UBS analyst Michael Goldsmith maintains Essential Properties (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EPRT#NYSE">EPRT</a>) with a Buy and lowers the price target from $40 to $37.

EPRT

UBS Maintains Buy on Essential Properties, Lowers Price Target to $37

iTeos Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) reported topline results from an updated interim analysis of the GALAXIES Lung-201 <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/g45372515/iteos-reports-topline-interim-results-from-galaxies-lung-201-study-of-belrestotug-dostarlimab-in-f" rel="noreferrer noopener">Phase 2 study on Tuesday</a>.
The trial sponsored by GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) assessed the belrestotug + dostarlimab doublet in previously untreated, unresectable, locally advanced, or metastatic PD-L1 high non-small <a target="_blank" href="https://www.benzinga.com/general/biotech" rel="noreferrer noopener">cell lung cancer (NSCLC)</a>.
The GALAXIES Lung-201 data demonstrated clinically meaningful improvements in the trial&#8217;s objective response rate (ORR) endpoint.
Also Read: <a target="_blank" href="https://www.benzinga.com//node/45100064" rel="noreferrer noopener">Britain&#8217;s GSK Asserts It Is &#8216;Well Positioned&#8217; To Mitigate Potential Tariffs After Strong Q1 Cancer And HIV Drug Sales</a>
However, the analysis did not meet established criteria for clinically meaningful improvements in the secondary endpoint of progression-free survival in the belrestotug + dostarlimab combination cohorts versus dostarlimab monotherapy.
An interim analysis of the GALAXIES H&amp;N-202 Phase 2 trial showed a trend below the meaningful threshold for ORR in the belrestotug combination cohorts vs. dostarlimab monotherapy in PD-L1 positive head and neck squamous cell carcinoma.
Based on these results, iTeos and GSK have decided to terminate the belrestotug development program and end the collaboration. All belrestotug-containing cohorts are ending, and any new enrollment in the ongoing GALAXIES Lung-301 Phase 3 trial will end.
iTeos Therapeutics said it is taking immediate steps to preserve capital and has initiated a targeted process to identify opportunities that preserve and maximize shareholder value. iTeos has engaged TD Cowen to advise on this process. 
&#8220;Given current market conditions and our appreciation of the responsibility to our valued shareholders, we believe the best path forward is to promptly evaluate a full range of strategic alternatives to unlock the value of our assets. With a strong balance sheet and a commitment to disciplined execution, we are well-positioned to pursue opportunities that maximize shareholder value,&#8221;&nbsp;said Michel Detheux, president and CEO of iTeos.
In April, iTeos said its cash and investments position was $624.3 million as of March 31, 2025, which is expected to provide a cash <a target="_blank" href="https://www.benzinga.com/pressreleases/25/04/g45053301/iteos-reports-first-quarter-2025-financial-results-and-provides-business-updates" rel="noreferrer noopener">runway into 2027</a>.
Price Action: ITOS stock is up 17.3% at $8.12 at the last check on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/news/earnings/25/05/45376829/cyberark-stock-slips-despite-strong-q1-growth-in-subscriptions-and-raised-2025-outlook" target="_blank" rel="noreferrer noopener">CyberArk Stock Slips Despite Strong Q1 Growth In Subscriptions And Raised 2025 Outlook</a></li>
</ul>
Photo by Aunt Spray via Shutterstock

Biotech

ITOS

iTeos Stock Soars Despite Trial Setback On Liquidation Buzz And Solid Cash Pile

Press Releases

Aurinia to Participate in Jefferies London Healthcare Conference

Aurinia Presents New Data Underscoring Critical Importance of Earlier Lupus Nephritis Detection and Intervention and Value of LUPKYNIS® in Managing LN at American College of Rheumatology Convergence 2024

Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis

Aurinia Pharmaceuticals to Release 2024 Fourth Quarter and Full Year Financial and Operational Results on February 27, 2025

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2024 and Provides Update on Recent Corporate Progress

Comments

Aurinia Pharmaceuticals

ニュース

最新ニュース Aurinia Pharmaceuticals (NASDAQ:AUPH) 株価情報

ニュース

パートナーシップ

ベンジンガ・グローバル